Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Radiant Research
mi
from
Santa Rosa, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Radiant Research
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Research Center for Clinical Studies, Inc.
mi
from
Norwalk, CT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Research Center for Clinical Studies, Inc.
mi
from
Norwalk, CT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Chase Medical Research, LLC
mi
from
Waterbury, CT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Brain Matters Research
mi
from
Delray Beach, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Brain Matters Research
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
MD Clinical
mi
from
Hallandale Beach, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Galiz Research
mi
from
Miami Springs, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Galiz Research
mi
from
Miami Springs, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Renstar Medical Research
mi
from
Ocala, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Compass Research LLC
mi
from
Orlando, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Princeton Medical Institute
mi
from
Princeton, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Princeton Medical Institute
mi
from
Princeton, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Memory Enhancement Center Of Nj, Inc.
mi
from
Toms River, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Brooklyn Medical Institute
mi
from
Brooklyn, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Brooklyn Medical Institute
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Advanced Bio-Behavioral Sciences, Inc
mi
from
Elmsford, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Advanced Bio-Behavioral Sciences, Inc
mi
from
Elmsford, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
University of Rochester Medical Center at MCH
mi
from
Rochester, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
University of Rochester Medical Center at MCH
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Summit Research Network
mi
from
Portland, OR
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Grayline Clinical Drug Trials
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The Memory Clinic
mi
from
Bennington, VT
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The Memory Clinic
mi
from
Bennington, VT
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The University of California Irvine
mi
from
Orange, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Meridien Research
mi
from
Brooksville, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Meridien Research
mi
from
Brooksville, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Social Psychiatry Research Institute
mi
from
Brooklyn, NY
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Social Psychiatry Research Institute
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Columbus Research and Wellness Institute
mi
from
Columbus, OH
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Columbus Research and Wellness Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
The Center for Excellence in Aging and Geriatric Health
mi
from
Williamsburg, VA
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
The Center for Excellence in Aging and Geriatric Health
mi
from
Williamsburg, VA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated:  3/28/2014
Clinical Site 1
mi
from
Bucharest,
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease
Status: Enrolling
Updated: 3/28/2014
Clinical Site 1
mi
from
Bucharest,
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Intergrated Medical and Behavioral Associates
mi
from
Glendale, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Intergrated Medical and Behavioral Associates
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Excell Research, Inc.
mi
from
Oceanside, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Excell Research, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
University of California, San Diego
mi
from
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Affiliated Research Institute
mi
from
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Affiliated Research Institute
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Scientific Clinical Research
mi
from
North Miami, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Scientific Clinical Research
mi
from
North Miami, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Uptown Research Institute, Llc
mi
from
Chicago, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Uptown Research Institute, Llc
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Alexian Brothers Behavioral Health
mi
from
Hoffman Estates, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Alexian Brothers Behavioral Health
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CBH Health LLC
mi
from
Rockville, MD
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CBH Health LLC
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Carolina Clinical Trials, Inc.
mi
from
Charleston, SC
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Carolina Clinical Trials, Inc.
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Vanderbilt Psychiatric Hospital
mi
from
Nashville, TN
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Vanderbilt Psychiatric Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
InSite Clinical Research LLC
mi
from
DeSoto, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
InSite Clinical Research LLC
mi
from
DeSoto, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
mi
from
Arkhangelsk,
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
mi
from
Arkhangelsk,
Click here to add this to my saved trials
Anticoagulation in AF Ablation and Effects on Neurocognitive Function
Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance
Status: Enrolling
Updated:  4/21/2014
University of California - San Francisco
mi
from
San Francisco, CA
Anticoagulation in AF Ablation and Effects on Neurocognitive Function
Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance
Status: Enrolling
Updated: 4/21/2014
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Whole Coffee Fruit Concentrate Pilot Study 1
Effects of Whole Coffee Fruit Concentrate On Cognition and Mood In Healthy Adults: A Pilot Clinical Study
Status: Enrolling
Updated:  5/19/2014
UCLA Semel Institute
mi
from
Los Angeles, CA
Whole Coffee Fruit Concentrate Pilot Study 1
Effects of Whole Coffee Fruit Concentrate On Cognition and Mood In Healthy Adults: A Pilot Clinical Study
Status: Enrolling
Updated: 5/19/2014
UCLA Semel Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated:  6/5/2014
Oregon Health and Science University
mi
from
Portland, OR
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status: Enrolling
Updated: 6/5/2014
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment
Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment
Status: Enrolling
Updated:  6/6/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment
Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment
Status: Enrolling
Updated: 6/6/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment
Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment
Status: Enrolling
Updated:  6/6/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment
Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment
Status: Enrolling
Updated: 6/6/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Effect of Phytochemicals on Aspects of Cognitive Performance
Effects of Phytochemicals on Aspects of Cognitive Performance
Status: Enrolling
Updated:  6/17/2014
Univerysity of Georgia
mi
from
Athens, GA
Effect of Phytochemicals on Aspects of Cognitive Performance
Effects of Phytochemicals on Aspects of Cognitive Performance
Status: Enrolling
Updated: 6/17/2014
Univerysity of Georgia
mi
from
Athens, GA
Click here to add this to my saved trials
On-line Treatment for Conduct Problems
Status: Enrolling
Updated:  6/18/2014
Yale Parenting Center
mi
from
New Haven, CT
On-line Treatment for Conduct Problems
Status: Enrolling
Updated: 6/18/2014
Yale Parenting Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy
Status: Enrolling
Updated:  7/9/2014
Stanford University
mi
from
Palo Alto, CA
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy
Status: Enrolling
Updated: 7/9/2014
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment: A Pilot Study
Status: Enrolling
Updated:  8/11/2014
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment
Virtual Reality Based Balance Training in People With Mild Cognitive Impairment: A Pilot Study
Status: Enrolling
Updated: 8/11/2014
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline
The Effect of Blueberry Consumption on Cognition and Body Composition in Elderly Who Are Experiencing Mild Cognitive Decline
Status: Enrolling
Updated:  9/6/2014
Nutrition Research Institute
mi
from
Kannapolis, NC
Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline
The Effect of Blueberry Consumption on Cognition and Body Composition in Elderly Who Are Experiencing Mild Cognitive Decline
Status: Enrolling
Updated: 9/6/2014
Nutrition Research Institute
mi
from
Kannapolis, NC
Click here to add this to my saved trials
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
Status: Enrolling
Updated:  9/20/2014
Joslin Diabetes Center
mi
from
Boston, MA
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery
Status: Enrolling
Updated: 9/20/2014
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
Status: Enrolling
Updated:  12/10/2014
Washington University School of Medicine/St. Louis Children's Hospital
mi
from
St. Louis, MO
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study
Status: Enrolling
Updated: 12/10/2014
Washington University School of Medicine/St. Louis Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials